Health Catalyst, Inc.

NASDAQ:HCAT

Medical - Healthcare Information Services

Healthcare
$1.29 -1.98%

-$0.04 today

Market cap
$98.24M
Beta
1.66
P/E (TTM)
-0.5
EPS (TTM)
-$3.65
52W Low $0.96High $4.13

Volume 0.27M

Average 1.24M

HCAT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Health Catalyst, Inc.NASDAQ: HCAT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $9.67M fell 36.3% year over year, behind the -24.0% change in trailing-twelve-month research & development. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at -13.0% a year.

Context

  • Research & development amounted to 16.0% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -36.3% toward the trailing-twelve-month pace of -24.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.67M-2.4% QoQ
Last fiscal yearDec 2025
$49.77M-14.1% YoY
LTMMar 2026
$44.26M-24.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.3%——
1 year-14.1%——
3-year CAGR-13.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
49.77M USD
Year-over-year change
-14.1%
4-year CAGR
-5.6%

Research & Development vs competitors

How HCAT compares with its peers on the latest reported figures

  • HCAT's LTM Mar 2026 research & development of $44.26M is the 7th highest of the 11 companies compared; the peer median is $61.43M.
  • Its year-over-year change of -24.0% is the 6th highest of 11, against a peer median of -22.7%.
  • Research & development amounts to 14.6% of revenue for HCAT, versus a peer median of 166.3%.
HCAT Competitors Peer median
Research & Development for HCAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M -24.6%-10.1%27721.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M +28.2%+38.4%184.8%
HCATHealth Catalyst, Inc.LTM Mar 2026$44.26M -24.0%-13.0%14.6%
OMOutset Medical, Inc.LTM Mar 2026$21.34M -31.8%-24.3%18.1%
NNOXNano-X Imaging Ltd.LTM Dec 2025$19.24M -4.7%-10.1%147.7%
HSDTSolana CompanyLTM Mar 2026$2.57M -32.8%-6.3%26.8%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$1.81M +151.4%+33.6%4.1%
Peer median (excluding HCAT) $61.43M-22.7%-5.7%166.3%

Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.93M276.24M295.94M306.58M311.14M
Cost of Revenue124.35M143.05M164.11M165.81M207M
Gross Profit117.57M133.19M131.83M140.78M104.13M
Gross Margin48.6%48.2%44.5%45.9%33.5%
Research & Development62.73M75.68M72.63M57.95M49.77M
Selling, General & Admin160.96M149.22M143.88M111.2M102.04M
Operating Expenses261.22M273.19M258.73M210.59M140.24M
Depreciation & Amortization41.11M51.53M42.22M41.43M50.5M
EBITDA(101.68M)(82.92M)(68.28M)(10.65M)(110.35M)
EBITDA Margin-42.0%-30.0%-23.1%-3.5%-35.5%
Operating Income(143.65M)(140.01M)(126.9M)(69.81M)(36.1M)
Operating Margin-59.4%-50.7%-42.9%-22.8%-11.6%
Interest Income831K5.69M16.39M17.98M7.54M
Interest Expense17.31M7.24M7.29M17.09M16.4M
Other Income / Expenses(16.46M)(1.68M)9.11M637K(141.15M)
Income Before Tax(160.11M)(141.68M)(117.79M)(69.17M)(177.26M)
Pre-Tax Margin-66.2%-51.3%-39.8%-22.6%-57.0%
Income Tax Expense(6.9M)(4.28M)356K333K716K
Net Income(153.21M)(137.4M)(118.15M)(69.5M)(177.97M)
Net Margin-63.3%-49.7%-39.9%-22.7%-57.2%
EPS (Basic)(3.23)(2.56)(2.09)(1.15)(2.55)
EPS (Diluted)(3.23)(2.54)(2.09)(1.15)(2.55)
Weighted Avg Shares47.49M53.72M56.42M60.19M69.9M
Weighted Avg Shares (Diluted)47.49M54.08M56.42M60.19M69.9M

Health Catalyst, Inc.

NASDAQ:HCAT

Intrinsic Alpha fair value

Locked

Current Price

$1.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.